Which drug is NOT part of the standard RIPE regimen for tuberculosis?

Prepare for the Adult-Gerontology Acute Care Nurse Practitioner Test. Study with interactive quizzes and detailed explanations. Boost your exam readiness with our diverse question formats and in-depth content coverage.

Multiple Choice

Which drug is NOT part of the standard RIPE regimen for tuberculosis?

The main concept is that standard first-line TB therapy uses four drugs together, known as RIPE: rifampin, isoniazid, pyrazinamide, and ethambutol. These agents are chosen because they have strong activity against Mycobacterium tuberculosis and work synergistically to rapidly kill bacilli and prevent resistance. Pyrazinamide helps shorten treatment and is particularly active in the acidic environments of granulomas, while ethambutol provides initial coverage to reduce the chance of resistance. Rifampin and isoniazid form the backbone due to their potent bactericidal effects. Metronidazole is not part of this standard regimen because its activity is mainly against anaerobic bacteria, and it does not reliably target Mycobacterium tuberculosis. It isn’t used in the initial RIPE phase, though other second-line or adjunctive therapies may be considered in drug-resistant TB.

The main concept is that standard first-line TB therapy uses four drugs together, known as RIPE: rifampin, isoniazid, pyrazinamide, and ethambutol. These agents are chosen because they have strong activity against Mycobacterium tuberculosis and work synergistically to rapidly kill bacilli and prevent resistance. Pyrazinamide helps shorten treatment and is particularly active in the acidic environments of granulomas, while ethambutol provides initial coverage to reduce the chance of resistance. Rifampin and isoniazid form the backbone due to their potent bactericidal effects.

Metronidazole is not part of this standard regimen because its activity is mainly against anaerobic bacteria, and it does not reliably target Mycobacterium tuberculosis. It isn’t used in the initial RIPE phase, though other second-line or adjunctive therapies may be considered in drug-resistant TB.

More practice questions